The most common AEs of any grade in selpercatinib were AST increase (61%), ALT increase (60%, hypertension (48%), diarrhea (44%), edema (41%), dry mouth (39%), blood bilirubin increase (37%), skin rash (33%), and fatigue (32%). This evidence concerns the gene GPT and exanthem.